Table 1.
Baseline clinical and demographic characteristics
| Characteristics | <6 yrs (n = 206) | 6–12 yrs (n = 278) | >12 yrs (n = 318) | Total (N = 802) | P value |
|---|---|---|---|---|---|
| Sex | 0.031 | ||||
| Female | 67 (32.5%) | 119 (42.8%) | 137 (43.1%) | 323 (40.3%) | |
| Male | 139 (67.5%) | 159 (57.2%) | 181 (56.9%) | 479 (59.7%) | |
| Age at transplantation | < 0.001 | ||||
| Median (IQR) | 4.92 (3.72–5.94) | 10.16 (8.50–11.3) | 16.09 (14.7–17.8) | 11.1 (6.85–15.3) | |
| Transplant era | 0.667 | ||||
| 08/1999-07/2014 | 108 (52.4%) | 140 (50.4%) | 154 (48.4%) | 402 (50.1%) | |
| 08/2014-04/2019 | 98 (47.6%) | 138 (49.6%) | 164 (51.6%) | 400 (49.9%) | |
| Donor type | 0.854 | ||||
| Deceased donor | 144 (69.9%) | 188 (67.6%) | 220 (69.2%) | 552 (68.8%) | |
| Living donor | 62 (30.1%) | 90 (32.4%) | 98 (30.8%) | 250 (31.2%) | |
| Follow-up time (months) | < 0.001 | ||||
| Median (IQR) | 54 (36, 84) | 54 (36, 78) | 48 (30, 60) | 48 (36, 72) | |
| Preemptive transplantation | 0.007 | ||||
| Yes | 28 (13.6%) | 68 (24.5%) | 75 (23.6%) | 171 (21.3%) | |
| Primary kidney disease | 0.002 | ||||
| CAKUT | 87 (42.2%) | 111 (39.9%) | 118 (37.1%) | 316 (39.4%) | |
| Cystic/hereditary/congenital diseases | 65 (31.6%) | 67 (24.1%) | 71 (22.3%) | 203 (25.3%) | |
| Primary glomerular disease | 32 (15.5%) | 45 (16.2%) | 64 (20.1%) | 141 (17.6%) | |
| Secondary glomerular disease/vasculitis | 6 (2.88%) | 25 (8.99%) | 18 (5.7%) | 49 (6.11%) | |
| Interstitial nephritis/pyelonephritis | 0 (0.00%) | 2 (0.72%) | 7 (2.2%) | 9 (1.12%) | |
| Neoplasms/tumors | 1 (0.49%) | 3 (1.08%) | 2 (0.6%) | 6 (0.75%) | |
| Unknown | 7 (3.40%) | 16 (5.76%) | 33 (10.4%) | 56 (6.98%) | |
| Other | 8 (3.88%) | 9 (3.24%) | 5 (1.6%) | 22 (2.74%) | |
| Number of HLA mismatches | |||||
| Overall | 0.353 | ||||
| Mean (SD) | 3.08 (1.49) | 2.92 (1.38) | 2.92 (1.38) | 2.96 (1.41) | |
| HLA-A | 0.136 | ||||
| Mean (SD) | 0.94 (0.66) | 0.94 (0.70) | 0.84 (0.68) | 0.90 (0.68) | |
| HLA-B | 0.128 | ||||
| Mean (SD) | 1.17 (0.71) | 1.05 (0.66) | 1.12 (0.63) | 1.11 (0.66) | |
| HLA-DR | 0.664 | ||||
| Mean (SD) | 0.98 (0.69) | 0.92 (0.66) | 0.96 (0.63) | 0.95 (0.66) | |
| Induction therapy | 0.007 | ||||
| Yes | 67 (32.5%) | 129 (46.4%) | 136 (42.8%) | 332 (41.4%) | |
| Previous kidney transplants | 0.005 | ||||
| Yes | 14 (6.80%) | 28 (10.1%) | 50 (15.7%) | 92 (11.5%) | |
| Cold ischemia time (hours, median (IQR)) | 0.359 | ||||
| Living donor | 2.50 (1.64–3.00) | 2.42 (1.94–3.25) | 2.50 (2.02–3.44) | 2.50 (2.00–3.25) | |
| Deceased donor | 14.1 (10.9–16.4) | 13.0 (10.2–16.0) | 13.9 (10.0–16.7) | 13.7 (10.2–16.4) | |
| Tacrolimus tradename | < 0.001 | ||||
| Prograf | 143 (69.7%) | 252 (91.0%) | 299 (94.6%) | 694 (87.0%) | |
| Modigraf | 61 (29.8%) | 12 (4.3%) | 5 (1.6%) | 78 (9.8%) | |
| Advagraf | 1 (0.49%) | 13 (4.7%) | 12 (3.8%) | 26 (3.3%) | |
| Immunosuppressive therapy at year 1 | |||||
| Tacrolimus | 206 (100%) | 278 (100%) | 318 (100%) | 802 (100%) | |
| MMF | 128 (62.1%) | 218 (78.4%) | 278 (87.4%) | 624 (77.8%) | < 0.001 |
| Azathioprine | 31 (15.1%) | 26 (9.25%) | 17 (5.35%) | 74 (9.2%) | 0.003 |
| Glucocorticoids | 160 (77.7%) | 220 (79.1%) | 284 (89.3) | 664 (82.8%) | 0.001 |
| Sirolimus | 2 (0.97%) | 1 (0.35%) | 2 (0.63%) | 5 (0.6%) | 0.861 |
| Everolimus | 13 (6.31%) | 9 (3.24%) | 12 (3.77%) | 34 (4.2%) | 0.406 |
CAKUT, congenital anomalies of the kidney and urogenital tract; HLA, human leukocyte antigen; IQR, interquartile range; MMF, mycophenolate mofetil.